Current Infectious Disease Reports

, Volume 2, Issue 1, pp 1–8

HIV and hepatitis virus infection

  • Michael A. Poles
  • Douglas T. Dieterich
Article

DOI: 10.1007/s11908-000-0078-9

Cite this article as:
Poles, M.A. & Dieterich, D.T. Curr Infect Dis Rep (2000) 2: 1. doi:10.1007/s11908-000-0078-9
  • 17 Downloads

Abstract

As the life expectancy of patients with HIV infection increases, greater attention will need to be focused on concurrent illnesses, such as viral hepatitis, that may increase mid- to long-range morbidity and mortality. The incidence of viral hepatitis is increased in patients with HIV disease, reflecting the epidemiologic risks that these two conditions share. Coinfection with HIV seems to adversely affect the natural history of hepatitis C but may actually reduce the hepatic damage associated with hepatitis B. Immunosuppression due to HIV does not seem to significantly affect hepatitis A, E, or G. Clinicians have been reluctant to treat viral hepatitis in the HIV-infected population, but this therapeutic nihilism is unwarranted. Most studies have concluded that the treatment of hepatitis C in HIV-infected patients results in an initial efficacy and a long-term response similar to those seen in the HIVseronegative population. Although the efficacy of interferon is reduced against hepatitis B, some nucleoside analogues are effective.

Copyright information

© Current Science Inc. 2000

Authors and Affiliations

  • Michael A. Poles
    • 1
  • Douglas T. Dieterich
    • 2
  1. 1.Division of Digestive Diseases, Center for the Health Sciences 44-138University of California, Los AngelesLos AngelesUSA
  2. 2.NYU Medical CenterNew YorkUSA